Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Accounts Payables: 2018-2025

Historic Accounts Payables for Neurogene (NGNE) over the last 6 years, with Sep 2025 value amounting to $1.5 million.

  • Neurogene's Accounts Payables fell 8.31% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 8.31%. This contributed to the annual value of $1.3 million for FY2024, which is 48.54% down from last year.
  • Per Neurogene's latest filing, its Accounts Payables stood at $1.5 million for Q3 2025, which was down 25.05% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, Neurogene's Accounts Payables registered a high of $5.4 million during Q1 2023, and its lowest value of $1.3 million during Q4 2024.
  • Over the past 3 years, Neurogene's median Accounts Payables value was $2.1 million (recorded in 2025), while the average stood at $2.5 million.
  • As far as peak fluctuations go, Neurogene's Accounts Payables crashed by 71.92% in 2024, and later spiked by 101.25% in 2025.
  • Quarterly analysis of 3 years shows Neurogene's Accounts Payables stood at $2.6 million in 2023, then plummeted by 48.54% to $1.3 million in 2024, then decreased by 8.31% to $1.5 million in 2025.
  • Its Accounts Payables stands at $1.5 million for Q3 2025, versus $2.1 million for Q2 2025 and $3.1 million for Q1 2025.